Exelixis | EXEL Stock Price, Company Overview & News - Forbes

In recent trading, shares of Exelixis Inc (NASD: EXEL) have crossed above the average analyst 12-month target price of $20.50, changing hands for $20.57/share. By Dividend Channel …

$20.50
OFF

Exelixis | EXEL Stock Price, Company Overview & News - Forbes

2 weeks from now

In recent trading, shares of Exelixis Inc (NASD: EXEL) have crossed above the average analyst 12-month target price of $20.50, changing hands for $20.57/share. By Dividend Channel …

forbes.com

$0.73
OFF

Exelixis (EXEL) Is An Incredible Growth Stock: 3 Reasons Why

2 weeks from now

Dec 9, 2024 · Right now, Exelixis has an S/TA ratio of 0.73, which means that the company gets $0.73 in sales for each dollar in assets. Comparing this to the industry average of 0.23, it can …

nasdaq.com

$42.00
OFF

Exelixis (EXEL) Receives A Buy From Truist Financial

2 weeks from now

1 day ago · In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $42.00. The …

businessinsider.com

03%
OFF

Why Exelixis (EXEL) Is Poised To Beat Earnings Estimates Again

2 weeks from now

2 days ago · For the previous quarter, the company was expected to post earnings of $0.37 per share and it actually produced earnings of $0.84 per share, delivering a surprise of 127.03%.

zacks.com

90%
OFF

Why Exelixis (EXEL) Is Poised To Beat Earnings Estimates Again

2 weeks from now

1 day ago · For the last reported quarter, Exelixis came out with earnings of $0.47 per share versus the Zacks Consensus Estimate of $0.42 per share, representing a surprise of 11.90%.

nasdaq.com

$2.16
OFF

Exelixis Sets 2025 Guidance In Line With Estimates (EXEL:NASDAQ)

2 weeks from now

3 days ago · Exelixis (NASDAQ:EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product revenues. The oncology …

seekingalpha.com

$36
OFF

EXEL - Exelixis Inc Stock Price And Quote - FINVIZ.com

2 weeks from now

Aug 7, 2012 · EXEL - Exelixis Inc - Stock screener for investors and traders, financial visualizations. Home: News: Screener: Maps: Groups: ... Exelixis price target raised to $36 …

finviz.com

FAQs about Exelixis | EXEL Stock Price, Company Overview & News - Forbes Coupon?

Where is Exelixis Inc headquartered?

Exelixis Inc is headquartered in Alameda, CA. The company was founded by Stelios Papadopoulos on November 15, 1994. Complete Exelixis Inc. stock information by Barron's. View real-time EXEL stock price and news, along with industry-best analysis. ...

Where can I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exelixis own? ...

Is Exelixis a good value stock?

EXEL boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Exelixis are trading at a forward earnings multiple of 14.8X, as well as a PEG Ratio of 0.5, a Price/Cash Flow ratio of 34.4X, and a Price/Sales ratio of 3.8X. ...

What was Exelixis' stock price on January 1st 2024?

Exelixis' stock was trading at $23.99 on January 1st, 2024. Since then, EXEL shares have increased by 49.3% and is now trading at $35.82. How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings results on Tuesday, October, 29th. ...

Are Exelixis insiders buying or selling more stock?

In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,508,610.00 in company stock. Only 2.85% of the stock of Exelixis is held by insiders. 85.27% of the stock of Exelixis is held by institutions. ...

What is Exelixis (Exel)?

Begin your TipRanks Premium journey today. Exelixis (EXEL) Company Description: Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. ...